Upgrade to SI Premium - Free Trial

Guggenheim Assumes Horizon Pharma (HZNP) at Buy

February 27, 2017 5:02 PM
Guggenheim initiates coverage on Horizon Pharma (NASDAQ: HZNP) with a Buy rating and a price target of $30.00.Analyst Brandon Folkes ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments New Coverage